BRANFORD, Conn.--(BUSINESS WIRE)--In preparation of product commercialization, Tangen Bioscience (Tangen) announced today that it has migrated its website from its old address: TangenBio, to a new address: https://tangenbioscience.com/. Tangen is working to update the contents of the new website, which will have a fresh new look in July. All Tangen employees’ email addresses will also be changed to: First Name.Last Name@tangenbioscience.com.

Since the onset of the COVID-19 pandemic, Tangen has focused resources to develop a test against COVID-19 supported by Biomedical Advanced Research and Development Authority (BARDA) (under the contract No. 75A50120C00085). Tangen is working on scaling up the manufacturing and will seek an Emergency Use Authorization for a 30-minute SARS-CoV-2 test to run on its portable GeneSpark™ instrument in the coming months.

About Tangen Bioscience, Inc.:

Tangen Bioscience, Inc. was founded in 2013 and is located in Branford, Connecticut. The company developed the TangenDx™ platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rotary rapid isothermal nucleic acid detection. The Tangen system consists of the TangenDx™ disc and the GeneSpark™ instrument, an automated amplification device. The TangenDx™ platform, which does not require laboratory facilities, is expected to deliver faster, simpler, more sensitive detection at a lower cost than other commercial technologies. Current tests in development include COVID-19, Candida auris, sepsis causing bacteria, antibiotic resistance genes, and a Candida blood panel. The TangenDx platform is on track for infectious disease clinical studies. To learn more, please visit: https://tangenbioscience.com/